Emerging from the UK, retatrutide, a novel molecule, is generating considerable buzz within the healthcare community regarding its ability for physique management . This dual GIP and GLP-1 agent agonist appears to provide a considerable benefit over existing therapies, showing promising results in initial clinical assessments. Researchers think its